About ERIs Life Sciences
ERIs Life Sciences is a company based in Ahmedabad (India) founded in 2007 by Amit Bakshi and Himanshu Shah. ERIs Life Sciences has raised $43 million across 1 funding round from investors including ChrysCapital. The company has 3,560 employees as of March 31, 2024. ERIs Life Sciences has completed 3 acquisitions, including Eris Oaknet Healthcare, Swiss Parenterals and Uth Healthcare. ERIs Life Sciences offers products and services including Branded Formulations and Patient Care Services.
- Headquarter Ahmedabad, India
- Employees 3560 as on 31 Mar, 2024
- Founders Amit Bakshi, Himanshu Shah
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Eris Lifesciences Ltd
-
Annual Revenue
$338.74 M (USD)44.02as on Mar 31, 2025
-
Net Profit
$41.2 M (USD)-10.26as on Mar 31, 2025
-
EBITDA
$120.44 M (USD)46.86as on Mar 31, 2025
-
Total Equity Funding
$43 M (USD)
in 1 rounds
-
Latest Funding Round
$43 M (USD), Series A
Sep 06, 2011
- Investors
-
Employee Count
3560
as on Mar 31, 2024
-
Investments & Acquisitions
Eris Oaknet Healthcare
& 2 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of ERIs Life Sciences
ERIs Life Sciences is a publicly listed company on the NSE with ticker symbol ERIS in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of ERIs Life Sciences
ERIs Life Sciences offers a comprehensive portfolio of products and services, including Branded Formulations and Patient Care Services.
Branded formulations are developed by Eris for chronic diseases, covering areas like cardio-metabolic therapies and emerging fields such as dermatology and nephrology.
Patient care services are offered by Eris, including diagnostic support for diabetes and cardiovascular conditions, along with initiatives for pain and gynaecological management.
People of ERIs Life Sciences
Unlock access to complete
Unlock access to complete
Funding Insights of ERIs Life Sciences
ERIs Life Sciences has successfully raised a total of $43M through 1 strategic funding round. The most recent funding activity was a Series A round of $43 million completed in September 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $43.0M
-
First Round
First Round
(06 Sep 2011)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2011 | Amount | Series A - ERIs Life Sciences | Valuation |
investors |
Investors in ERIs Life Sciences
ERIs Life Sciences has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include ChrysCapital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment firm focusing on private equity in sectors like financial services and healthcare.
|
Founded Year | Domain | Location |
Investments & Acquisitions by ERIs Life Sciences
ERIs Life Sciences has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Eris Oaknet Healthcare, Swiss Parenterals and Uth Healthcare.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Pharmaceutical products are manufactured by Eris Oaknet Healthcare in India.
|
2011 | ||||
|
Distributor of diabetes, obesity, and other drugs
|
2011 | ||||
|
Contract development and manufacturing for pharmaceutical products are offered.
|
1986 |
Financial Statements - ERIs Life Sciences
Eris Life Sciences Comparisons
Competitors of ERIs Life Sciences
Frequently Asked Questions about ERIs Life Sciences
ERIs Life Sciences was founded in 2007 and raised its 1st funding round 4 years after it was founded.
ERIs Life Sciences is headquartered in Ahmedabad, India. It is registered at Ahmedabad, Gujarat, India.
ERIs Life Sciences is a funded company, having raised a total of $43M across 1 funding round to date. The company's 1st funding round was a Series A of $43M, raised on Sep 06, 2011.
As of Mar 31, 2024, the latest employee count at ERIs Life Sciences is 3,560.
Annual revenue of ERIs Life Sciences is $338.74M as on Mar 31, 2025.
ERIs Life Sciences was founded in 2007 in Ahmedabad, India, within the pharmaceutical sector. Formulations for chronic diseases, particularly cardio-metabolic therapies, are produced. Expansion into dermatology, neuropsychiatry, womens health, and nephrology is underway. Studies are conducted, and patient care initiatives are offered to support diagnosis and management of chronic conditions across therapeutic areas.
ERIs Life Sciences offers Branded Formulations and Patient Care Services.
Yes, ERIs Life Sciences is publicly traded on NSE under the ticker symbol ERIS.
ERIs Life Sciences has made 3 acquisitions, including Eris Oaknet Healthcare, Swiss Parenterals, and Uth Healthcare.
ERIs Life Sciences has 1 investor. Key investors include ChrysCapital.
The ticker symbol of ERIs Life Sciences is ERIS on NSE.